Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, GeneDx Partner With University of Washington on Whole-Genome Sequencing Study in Kids

NEW YORK – Illumina, GeneDx, and the University of Washington School of Medicine Brotman Baty Institute for Precision Medicine are collaborating on a study using whole-genome sequencing to diagnose children with suspected developmental differences and critically ill infants.

The SeqFirst study will provide WGS to 100 children suspected of having developmental differences. GeneDx will perform sequencing with reagents provided by Illumina. Researchers will review medical records of participants for two years after enrollment and complete the study in three years. After one year, the team will report interim results and make recommendations for improvements to existing policies in genetic testing.

In another branch of the study, the researchers will provide WGS for critically ill infants immediately upon hospitalization at Seattle Children's Hospital. GeneDx will provide the laboratory-based testing. SeqFirst hopes to enroll 100 patients in neonatal intensive care units, or NICUs, and show improved outcomes due to earlier diagnoses and demonstrate the cost effectiveness of WGS as a first-line test.

In August 2020, GeneDx, part of Opko Health, signed a deal to provide genomic services to NICUs associated with Pediatrix Medical Group.

In August 2019, Illumina launched a newborn sequencing study with the Children's Hospital of Fudan University in China.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.